Double-blind trial of recombinant gamma-interferon versus placebo in the treatment of rheumatoid arthritis.
One hundred five patients were enrolled in a 12-week, randomized, prospective, double-blind, placebo-controlled trial of recombinant human gamma-interferon (rHu gamma-IFN) for the treatment of rheumatoid arthritis. Fifty-four patients received rHu gamma-IFN and 51 received placebo. Forty-two patients in each group completed the 12-week trial. Some clinical improvement occurred in both groups of patients. Although the improvement with rHu gamma-IFN was greater than that with placebo, the differences were generally not statistically significant.
Cannon
G W
GW
University of Utah, Salt Lake City.
Pincus
S H
SH
Emkey
R D
RD
Denes
A
A
Cohen
S A
SA
Wolfe
F
F
Saway
P A
PA
Jaffer
A M
AM
Weaver
A L
AL
Cogen
L
L
D000328:Adult; D000368:Aged; D000954:Antigens, Surface / Q000378:metabolism; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology / Q000378:metabolism; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004361:Drug Tolerance; D005260:Female; D006801:Humans; D007371:Interferon-gamma / Q000009:adverse effects / Q000627:therapeutic use*; D007962:Leukocytes / Q000276:immunology / Q000378:metabolism; D008297:Male; D008565:Membrane Proteins / Q000378:metabolism; D008875:Middle Aged; D010919:Placebos / Q000627:therapeutic use*; D011994:Recombinant Proteins; D013997:Time Factors
D000954:Antigens, Surface; D008565:Membrane Proteins; D010919:Placebos; D011994:Recombinant Proteins; D007371:Interferon-gamma